Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature [0.03%]
靶向CD38单克隆抗体治疗染色体1q拷贝数异常多发性骨髓瘤的疗效及机制：文献回顾
Emiliano Barbieri,Enrica Antonia Martino,Elena Rivolti et al.
Emiliano Barbieri et al.
Introduction: Gain/amplification of 1q (+1q) represents one of the most prevalent cytogenetic abnormalities (CAs) observed in multiple myeloma (MM). Historical studies predating the advent of anti-CD38 monoclonal antibodi...
Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis [0.03%]
一项在中国绝经后女性骨质疏松症患者中评估MW031疗效和安全性的随机、双盲、安慰剂对照、多中心研究
Yan Jiang,Yanan Huo,Yufeng Li et al.
Yan Jiang et al.
Background: This study aimed to assess the efficacy and safety of MW031 in Chinese postmenopausal women with osteoporosis. Patients and methods: ...
Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF) [0.03%]
两项阿达木单抗-艾勃莫药物在健康志愿者中的相对生物利用度、免疫原性及安全性：一项双盲随机、单次给药、平行对照I期临床试验（VOLTAIRE-HCLF）
Viktoria Moschetti,Susanne Buschke,Julia Bertulis et al.
Viktoria Moschetti et al.
Objective: VOLTAIRE-HCLF compared the relative bioavailability of citrate-free high-concentration and reference formulations of the biosimilar adalimumab-adbm (Cyltezo®), including pharmacokinetic (PK) profiles, immunoge...
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma [0.03%]
针对多发性骨髓瘤患者的一种BCMA靶向CAR-T疗法cilta-cel
Sundar Jagannath,Carolyn C Jackson,Jordan M Schecter et al.
Sundar Jagannath et al.
Introduction: Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting CAR-T therapy, is approved in the United States and Europe for patients with relapsed/refractory multiple myeloma (RRMM) and ≥1 prior line of therapy ...
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives [0.03%]
儿童和青少年慢性自发性荨麻疹的生物制剂治疗：现状、挑战与未来展望
Katharina Marlies Duda,Bettina Wedi
Katharina Marlies Duda
Introduction: Chronic spontaneous urticaria (CSU) poses significant challenges, especially in pediatric and adolescent patients, impacting physical, emotional, and social well-being. Recent biologic breakthroughs offer pr...
William David Wells-Gatnik,Paolo Martelletti
William David Wells-Gatnik
Introduction: Approximately 50% of patients that receive a CGRP(r) MoAb for the preventative treatment of migraine are expected to discontinue therapy. For patients that discontinue CGRP(r) MoAb therapy, few clinical opti...
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients [0.03%]
CAR-T治疗后大B细胞淋巴瘤患者一线挽救治疗反应率的 meta 分析
Jaromir Tomasik,Dominik Bilicki,Grzegorz Władysław Basak
Jaromir Tomasik
Introduction: The prognosis for large B-cell lymphoma (LBCL) patients who did not respond or relapsed after chimeric antigen receptor (CAR)-T therapy remains dismal, with no established consensus on the most effective sal...
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting [0.03%]
针对成人B细胞淋巴瘤的CD20xCD3双特异性抗体免疫治疗：来自美国血液学学会（ASH）2023年年会的见解
Hao Sun,Haizhou Xing,Lijie Han et al.
Hao Sun et al.
Introduction: At the 65th American Society of Hematology (ASH) 2023 Annual Meeting, the latest advancements in CD20×CD3 BsAbs for B-cell lymphoma (BCL) were highlighted, particularly in relapsed/refractory (R/R) follicul...
Biosimilars and access to biologic therapy in immune-mediated diseases [0.03%]
类似药与自身免疫性疾病生物制剂治疗的可及性
Rocío Vázquez-Sánchez,Marco Navarro-Dávila,Esther Ramírez Herráiz et al.
Rocío Vázquez-Sánchez et al.
Background: The rise of biologic agents has been a major breakthrough in treating immune-mediated inflammatory diseases (IMIDs). However, their high cost underscores the need for strategies to optimize treatment efficienc...
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study [0.03%]
生物类似药曲妥珠单抗（CT-P6）在韩国实际应用中的有效性和安全性：上市后监测研究
Min Ho Park,Jae Hong Seo,Jung Ho Park et al.
Min Ho Park et al.
Background: The trastuzumab biosimilar CT-P6 is approved for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC), metastatic breast cancer (MBC), and metastatic gastric cancer (MGC). The obj...
Observational Study
Expert opinion on biological therapy. 2024 Apr;24(4):305-312. DOI:10.1080/14712598.2024.2334386 2024